Company: HURA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0000950170-25-108972
Chunk: 6

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 6
---
 of which $15.0 million was paid in the form of Legacy TuHURA common stock), and $16.2 million and $10.1 million for the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025, we had an accumulated deficit of $127.3 million. Our operating losses may fluctuate significantly from quarter-to-quarter and year-to-year as a result of several factors, including the timing of our preclinical studies and clinical trials and the expenditures related to other research and development activities. We expect to continue to incur operating losses. We anticipate these losses will increase substantially as it advances our product candidates through preclinical and clinical development, develops additional product candidates and seeks regulatory approvals for our product candidates. We do not